应用双重算法筛查梅毒:低梅毒流行人群中不一致与一致血清学结果分析
在110663份血清样本中平行比较传统筛查算法(TSA)与逆向筛查算法(RSA)的性能。RSA检出2259份(2.0%)化学发光免疫分析(CIA)反应性结果,其中377份(16.7%)梅毒螺旋体颗粒凝集试验(TPPA)无反应;TSA检出934份(0.8%)甲苯胺红不加热血清试验(TRUST)反应性结果,其中67份(7.2%)TPPA无反应。RSA检出更多梅毒螺旋体血清学反应性患者,但可能假反应率也增高。
要点
- RSA检出2259份(2.0%)CIA反应性结果,其中377份(16.7%)TPPA无反应。
- TSA检出934份(0.8%)TRUST反应性结果,其中67份(7.2%)TPPA无反应。
- RSA中CIA反应性/TRUST反应性结果共867份,其中27份(3.1%)TPPA无反应。
核心结论
- RSA检出更多梅毒螺旋体血清学反应性患者,但相比TSA可能假反应率增高,尤其低指数值和TRUST无反应性结果需用第二种梅毒螺旋体试验复测。
研究设计与样本
- 研究对110663份梅毒筛查血清样本平行进行化学发光免疫分析(CIA)和甲苯胺红不加热血清试验(TRUST)。
- RSA中CIA反应性血清反射性检测TRUST并用梅毒螺旋体颗粒凝集试验(TPPA)确认,TSA中TRUST反应性血清随后检测TPPA。
主要发现
- RSA检出2259份(2.0%)CIA反应性结果,其中377份(16.7%)TPPA无反应;TSA检出934份(0.8%)TRUST反应性结果,其中67份(7.2%)TPPA无反应。
- 2259份CIA反应性结果中1392份(61.6%)TRUST无反应,其中350份(25.1%)TPPA无反应。
- 350份TPPA无反应血清中182份进一步用第二种CIA(VITROS Syphilis TPA,VITROS TPA)检测,155份(85.2%)无反应、27份(14.8%)反应。
- 27份VITROS TPA反应性血清进一步用梅毒螺旋体Western blot(Euroimmun IgG Western Blot,EuroWB)检测,11份(41%)不确定、6份(22%)无反应、10份(37%)反应。
- 10份EuroWB反应性血清中2份在1年随访后TPPA转为1:80+/-;867份CIA反应性/TRUST反应性结果中27份(3.1%)TPPA无反应。
关键数值与推荐
- RSA检出CIA反应性2259份(2.0%),其中TPPA无反应377份(16.7%)。
- TSA检出TRUST反应性934份(0.8%),其中TPPA无反应67份(7.2%)。
- CIA反应性结果中TRUST无反应1392份(61.6%),其中TPPA无反应350份(25.1%)。
- 350份TPPA无反应血清中182份用VITROS TPA检测,无反应155份(85.2%)、反应27份(14.8%)。
- 27份VITROS TPA反应性血清用EuroWB检测,不确定11份(41%)、无反应6份(22%)、反应10份(37%)。
临床怎么用
- RSA筛查的CIA反应性结果中,低指数值和TRUST无反应性结果需用第二种梅毒螺旋体试验复测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Currently, many laboratories have switched the traditional screening algorithm (TSA) to reverse screening algorithm (RSA) for the efficiencies in high-volume syphilis screening. However, confusions have been arisen regarding this paradigm shift. OBJECTIVE: To compare the performance of two algorithms with head-to-head mode. METHODS: Sera screening for syphilis were tested in parallel with chemiluminescence immunoassay (CIA) and toluidine red unheated serum test (TRUST). CIA-reactive sera from the RSA were reflexively tested with TRUST and confirmed with Treponema pallidum particle agglutination assay (TPPA), while the TRUST-reactive serology from the TSA were afterwards tested with TPPA. RESULTS: A total of 110 663 serum samples were screened. The RSA identified 2259 (2.0%) CIA-reactive results, of which 377 (16.7%) showed TPPA nonreactive results, while the TSA identified 934 (0.8%) TRUST-reactive results, of which 67 (7.2%) showed TPPA-nonreactive results. Among the 2259 CIA-reactive results, 1392 (61.6%) were TRUST-nonreactive, of which 350 (25.1%) were TPPA-nonreactive. A total of 182 sera from the 350 TPPA-nonreactive sera were further tested by a second CIA (VITROS Syphilis TPA, VITROS TPA), of which 155 (85.2%) were nonreactive and 27 (14.8%) were reactive. The 27 VITROS TPA-reactive sera were further tested with a treponemal Western blot assay (Euroimmun IgG Western Blot, EuroWB), of which 11 (41%) were indeterminate, 6 (22%) were nonreactive and 10 (37%) were reactive. Among the 10 EuroWB-reactive sera, two seroconverted to TPPA 1:80+/- after 1-year follow-up. Of 867 CIA-reactive/TRUST-reactive results, 27 (3.1%) were TPPA-nonreactive. CONCLUSIONS: The RSA identified more patients with reactive treponemal serology. However, it also yielded an increased likely false-reactive rate compared with the TSA, especially those results with low index values and TRUST-nonreactive serology, were necessary to retest with a second treponemal test. Further testing results with TPPA, VITROS TPA and EuroWB suggested the false-reactive CIA screening results and the likely false-nonreactive TPPA results when the reactive treponemal results screened with RSA were to be identified.
引用
- Zhuang YH, Liu H, Tang J, et al. Screening for syphilis with dual algorithms: analysis of discordant and concordant serology results in a population with a low prevalence of syphilis. J Eur Acad Dermatol Venereol. 2018. PMID: 30223307. doi:10.1111/jdv.15251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。